Огляд
Select a topic to solve related cases or follow a course topic
-
Topic 1Acute COVID-19 in special populations
-
Topic 2Initial treatment of MIBC
-
Topic 3New hope for patients progressing after prior treatment for mUCa
-
Topic 4Immunotherapy and antibody-drug conjugates: handling AEs and special populations
-
Topic 5First-line therapy of synchronous and metachronous metastatic UCa
-
Topic 6Histological subtypes of (N)MIBC: managed differently compared to pure UCa?
-
Topic 7Adjuvant treatment approaches for MIBC
-
Topic 8COVID-19 vaccines
-
Topic 9Treatment of acute COVID-19
-
Topic 10High-risk non-metastatic prostate cancer: the devil is in the details
-
Topic 11Long COVID
-
Topic 12Початкове лікування болю внаслідок остеоартриту
-
Topic 13Які є варіанти після невдалого лікування?
-
Topic 14Лікування болю при остеоартрозі у пацієнтів із супутніми захворюваннями
-
Topic 15Скерування на подальше спостереження хронічного болю, пов'язаного з остеоартритом
-
Topic 16High-risk non-metastatic prostate cancer
-
Topic 17Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 18Finding the right ADT for the right patient
-
Topic 19Follow-up surveillance regimes for low-/intermediate-risk NMIBC
-
Topic 20Treatment of high-risk PCa: the basics
-
Topic 21Oligometastatic PCa: treating the primary and/or metastases
-
Topic 22Biochemical recurrence after radical prostatectomy
-
Topic 23CRPC: treatment in daily clinical practice
-
Topic 24mCRPC: novel and emerging agents
-
Topic 25Treatment of low and intermediate-risk PCa
-
Topic 26Active surveillance: yes or no?
-
Topic 27Adverse pathology at radical prostatectomy
-
Topic 28Finding the right ADT for the right patient
-
Topic 29Tailoring treatment for metastatic hormone-sensitive prostate cancer
-
Topic 30Management of non-neurogenic female OAB
-
Topic 31Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
-
Topic 32Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
-
Topic 33Male LUTS: keep on learning
-
Topic 34Initial management of nocturia
-
Topic 35First-line systemic therapy in metastatic renal cell carcinoma
-
Topic 36UPDATED --- Systemic therapy for HER2-positive early breast cancer
-
Topic 37Systemic therapy for mRCC: second line and beyond
-
Topic 38UPDATED --- Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
-
Topic 39Management of small renal masses
-
Topic 40UPDATED --- Adjuvant systemic treatment of luminal A/B early breast cancer in postmenopausal women
-
Topic 41NEW --- Systemic therapy for early stage TNBC
-
Topic 42Local therapy for mRCC
-
Topic 43UPDATED --- Radiotherapy for early breast cancer
-
Topic 44Management of HER2+ MBC
-
Topic 45Brain metastases in patients with HER2+ breast cancer
-
Topic 46CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer
-
Topic 47Theragnostic testing – choosing the right therapy in mTNBC
-
Topic 48Challenges in high-risk NMIBC